All trial regimens evaluated were safe, but the five-day regimen offered the best balance of safety and efficacy ORLANDO, DECEMBER 7, 2025 – Patients with lower-risk myelodysplastic syndromes (MDS) ...

The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible ...

Please provide your email address to receive an email when new articles are posted on . A 5-day azacitidine course had the most consistent survival benefit for low-risk MDS vs. other shorter ...

INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs)—Study design informed by ...

Please provide your email address to receive an email when new articles are posted on . In this video, Eunice Wang, MD, discusses the use of venetoclax azacitidine as a standard of care therapy for ...

Investigators say oral formulations of hypomethylating agents could be a significant advancement for people with myelodysplastic syndromes and acute myeloid leukemia. Oral hypomethylating agents (HMAs ...

The phase 3 VERONA trial did not meet the primary endpoint of overall survival. Topline data were announced from a phase 3 trial evaluating venetoclax (Venclexta ®) plus azacitidine for patients with ...

Incidence of unconventional infections (UC) in patients with acute myelogenous leukemia (AML) treated with clofarabine (CLO)-containing induction therapy. Background: Hypomethylating drugs are active ...

– Every year in the United States, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS), and there remains a high unmet need for new treatment options – – The designation is ...